Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.15, Zacks reports. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Stock Performance

SUPN stock traded up $0.13 during mid-day trading on Tuesday, hitting $32.81. The company had a trading volume of 961,698 shares, compared to its average volume of 458,164. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28. The stock’s fifty day moving average price is $37.41 and its two-hundred day moving average price is $35.39. The firm has a market cap of $1.81 billion, a PE ratio of 30.66 and a beta of 0.90.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $57.00 to $36.00 in a research report on Wednesday, February 19th.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 in the last quarter. Insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.